Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
TTLC 2019
IASLC 2019 Targeted Therapies of Lung Cancer Meeting
Access to all slides from presentations that occur during the IASLC 2019 Targeted Therapies of Lung Cancer Meeting in Santa Monica, CA
Presentation Date(s):- Feb 20 - 23, 2019
- Total Presentations: 232
-
+
11 - Surgically Resectable
- Type: General Session
- Track:
- Presentations: 10
- Slides Available
- Moderators:Nasser Altorki
- Coordinates: 2/22/2019, 08:00 - 09:05, Starlight Ballroom
-
+
Surgery Considerations After IO or TKI (Slides Available)
07:00 - 07:05 | Author(s): Erin Gillaspie
- Abstract
No abstract available for this presentation
-
+
Neoadjuvant Atezolizumab (LCMC3) and Pembrolizumab (Slides Available)
07:05 - 07:10 | Author(s): Jay Lee
- Abstract
No abstract available for this presentation
-
+
Neoadjuvant Chemo + Atezolizumab (Slides Available)
07:10 - 07:15 | Author(s): Catherine Shu
- Abstract
No abstract available for this presentation
-
+
Neoadjuvant Nivolumab +/- Ipilimumab (NEOSTAR) (Slides Available)
07:15 - 07:20 | Author(s): Tina Cascone
- Abstract
No abstract available for this presentation
-
+
Adjuvant IO (Slides Available)
07:20 - 07:25 | Author(s): Penelope Bradbury
- Abstract
No abstract available for this presentation
-
+
Adjuvant Alchemist ALK TKIs (Slides Available)
07:25 - 07:30 | Author(s): David Gerber
- Abstract
No abstract available for this presentation
-
+
Osimertinib EGFR Mutant (Slides Available)
07:30 - 07:35 | Author(s): Collin Blakely
- Abstract
No abstract available for this presentation
-
+
Neoadjuvant Crizotinib ALK ROS and MET (Slides Available)
07:35 - 07:40 | Author(s): Caroline McCoach
- Abstract
No abstract available for this presentation
-
+
LCMC4 Umbrella (Slides Available)
07:40 - 07:45 | Author(s): Jamie Chaft
- Abstract
No abstract available for this presentation
-
+
Science (Slides Available)
07:45 - 07:55 | Author(s): David Harpole
- Abstract
No abstract available for this presentation
-
+
12 - Debate #2 Neoadjuvant/Adjuvant CT+IO Is Most Likely to Cure the Most Patients
- Type: General Session
- Track:
- Presentations: 2
- Slides Available
- Moderators:Wolf Lindwasser
- Coordinates: 2/22/2019, 09:05 - 09:20, Starlight Ballroom
-
+
Neoadjuvant Is Best (Slides Available)
08:05 - 08:20 | Author(s): Paul A. Bunn Jr.
- Abstract
No abstract available for this presentation
-
+
Adjuvant Is Best (Slides Available)
08:05 - 08:20 | Author(s): Martin Edelman
- Abstract
No abstract available for this presentation
-
+
13 - Vaccines and Agents Targeting Tumor Microenvironment
- Type: General Session
- Track:
- Presentations: 8
- Slides Available
- Moderators:Thomas Marron
- Coordinates: 2/22/2019, 09:20 - 10:20, Starlight Ballroom
-
+
IO + B7-H3
08:20 - 08:25 | Author(s): Charu Aggarwal
- Abstract
No abstract available for this presentation
-
+
IO + HDAC (Slides Available)
08:25 - 08:30 | Author(s): Ronan Kelly
- Abstract
No abstract available for this presentation
-
+
IO + Hypomethylating Agents (Slides Available)
08:30 - 08:35 | Author(s): Kristen Marrone
- Abstract
No abstract available for this presentation
-
+
Viagenpumatucel TGFb Vaccine (Slides Available)
08:35 - 08:40 | Author(s): Daniel Morgensztern
- Abstract
No abstract available for this presentation
-
+
NEO-PV1 (Slides Available)
08:40 - 08:45 | Author(s): Kathryn Arbour
- Abstract
No abstract available for this presentation
-
+
TIL + Nivolumab (Slides Available)
08:45 - 08:50 | Author(s): Benjamin Creelan
- Abstract
No abstract available for this presentation
-
+
Cell Therapy NY-ESO TCR (Slides Available)
08:50 - 08:55 | Author(s): Vincent Lam
- Abstract
No abstract available for this presentation
-
+
Science (Slides Available)
08:55 - 09:05 | Author(s): Naiyer Rizvi
- Abstract
No abstract available for this presentation
-
+
14 - HER2/3 and Exon 20
- Type: General Session
- Track:
- Presentations: 12
- Slides Available
- Moderators:Dara Aisner
- Coordinates: 2/22/2019, 10:45 - 11:55, Starlight Ballroom
-
+
Poziotinib (Slides Available)
09:45 - 09:50 | Author(s): Jacqulyne Robichaux
- Abstract
No abstract available for this presentation
-
+
Osimertinib (Slides Available)
09:50 - 09:55 | Author(s): Zofia Piotrowska
- Abstract
No abstract available for this presentation
-
+
Tak 788 (Slides Available)
09:55 - 10:00 | Author(s): Jack West
- Abstract
No abstract available for this presentation
-
+
Tarloxotinib (Hypoxia Activated EGFR) (Slides Available)
10:00 - 10:05 | Author(s): Viola Zhu
- Abstract
No abstract available for this presentation
-
+
Trastuzumab and Ado-trastuzumab (Slides Available)
10:05 - 10:10 | Author(s): Bob Li
- Abstract
No abstract available for this presentation
-
+
Pertuzumab (HER 2) (Slides Available)
10:10 - 10:15 | Author(s): Thomas Stinchcombe
- Abstract
No abstract available for this presentation
-
+
DS8201 (Trastuzumab Derutecam) (Slides Available)
10:15 - 10:20 | Author(s): Pasi Janne
- Abstract
No abstract available for this presentation
-
+
TAS0728 (HER 2)
10:20 - 10:25 | Author(s): Rathi Pillai
- Abstract
No abstract available for this presentation
-
+
Pyrotinib (HER 2) (Slides Available)
10:25 - 10:30 | Author(s): George Simon
- Abstract
No abstract available for this presentation
-
+
MM 121 Seribentumab
10:30 - 10:35 | Author(s): Lecia Sequist
- Abstract
No abstract available for this presentation
-
+
ADCT-502 (HER 2 ADC)
10:35 - 10:40 | Author(s): Grace Dy
- Abstract
No abstract available for this presentation
-
+
Where to Next?
10:40 - 10:50 | Author(s): Robert Doebele
- Abstract
No abstract available for this presentation
-
+
15 - Stage 3 NSCLC
- Type: General Session
- Track:
- Presentations: 9
- Slides Available
- Moderators:Joe Pater
- Coordinates: 2/22/2019, 11:55 - 12:55, Starlight Ballroom
-
+
Durvalumab (Slides Available)
10:55 - 11:00 | Author(s): Jhanelle Gray
- Abstract
No abstract available for this presentation
-
+
Pembrolizumab (Slides Available)
11:00 - 11:05 | Author(s): Nasser Hanna
- Abstract
No abstract available for this presentation
-
+
Nivolumab NICOLAS Study (Slides Available)
11:05 - 11:10 | Author(s): Scott Gettinger
- Abstract
No abstract available for this presentation
-
+
ECOG-ACRIN 5181 (Slides Available)
11:10 - 11:15 | Author(s): Nathan Pennell
- Abstract
No abstract available for this presentation
-
+
ChemoRT Followed by Nivo + Ipi (Slides Available)
11:15 - 11:20 | Author(s): Nasser Hanna
- Abstract
No abstract available for this presentation
-
+
ChemoRT + Metformin (Slides Available)
11:20 - 11:25 | Author(s): Theodoros Tsakiridis
- Abstract
No abstract available for this presentation
-
+
SBRT Plus PD-1 Inhibition (Slides Available)
11:25 - 11:30 | Author(s): Christine Bestvina
- Abstract
No abstract available for this presentation
-
+
Proton Therapy in NSCLC (Slides Available)
11:30 - 11:35 | Author(s): Walter Curran
- Abstract
No abstract available for this presentation
-
+
Science of Radiation Induced Immune Stimulation
11:35 - 11:45 | Author(s): James Welsh
- Abstract
No abstract available for this presentation
-
+
16 - Best Fellows Abstract Oral Presentations
- Type: General Session
- Track:
- Presentations: 4
- Slides Available
- Moderators:Leora Horn
- Coordinates: 2/22/2019, 14:00 - 15:00, Starlight Ballroom
-
+
IL-6, IL-8 Drive LAG3/PD1 Immune Suppression on Effector and Naïve, Peripheral Blood CD8+ T Cells in Lung Cancer Patients (Slides Available)
13:00 - 13:10 | Author(s): Ashwin Somasundaram
- Abstract
No abstract available for this presentation
-
+
Standardization of Tumor Mutational Burden (TMB) Quantification and Thresholds in NSCLC (Slides Available)
13:15 - 13:25 | Author(s): Natalie Vokes
- Abstract
No abstract available for this presentation
-
+
Neoadjuvant Nivolumab in Resectable Non-small Cell Lung Cancer: Long-term Clinical Follow-up With Longitudinal Molecular and Immunologic Responses (Slides Available)
13:30 - 13:40 | Author(s): Joshua Reuss
- Abstract
No abstract available for this presentation
-
+
The Molecular Landscape of Resistance to Osimertinib in EGFR-mutant Non-small Cell Lung Cancers
13:45 - 13:55 | Author(s): Adam Schoenfeld
- Abstract
No abstract available for this presentation
-
+
17 - Miscellaneous
- Type: General Session
- Track:
- Presentations: 13
- Slides Available
- Moderators:Bob Keith
- Coordinates: 2/22/2019, 15:00 - 16:20, Starlight Ballroom
-
+
Selinexor (Slides Available)
14:00 - 14:05 | Author(s): David Gerber
- Abstract
No abstract available for this presentation
-
+
Trabectadin (Slides Available)
14:05 - 14:10 | Author(s): Jose Pacheco
- Abstract
No abstract available for this presentation
-
+
Pinabulin +/- Others (Slides Available)
14:10 - 14:15 | Author(s): Lyudmila Bazhenova
- Abstract
No abstract available for this presentation
-
+
CB839 Glutaminase Inhibitor (Slides Available)
14:15 - 14:20 | Author(s): Aaron Lisberg
- Abstract
No abstract available for this presentation
-
+
BBI6089 (Slides Available)
14:20 - 14:25 | Author(s): Gregory Otterson
- Abstract
No abstract available for this presentation
-
+
SGN2FF (Fucosylation) (Slides Available)
14:25 - 14:30 | Author(s): Karen Reckamp
- Abstract
No abstract available for this presentation
-
+
Pevonedistat (NEDD8) (Slides Available)
14:30 - 14:35 | Author(s): Angel Qin
- Abstract
No abstract available for this presentation
-
+
Nanocisplatin NC6004 (Slides Available)
14:35 - 14:40 | Author(s): Lyudmila Bazhenova
- Abstract
No abstract available for this presentation
-
+
SMAC Mimetics (Slides Available)
14:40 - 14:50 | Author(s): Glenwood Goss
- Abstract
No abstract available for this presentation
-
+
Agios (Slides Available)
14:45 - 14:50 | Author(s): Frederick Wilson
- Abstract
No abstract available for this presentation
-
+
Sapacitabine (Slides Available)
14:50 - 14:55 | Author(s): Philip Bonomi
- Abstract
No abstract available for this presentation
-
+
FAK Inhibition (Slides Available)
14:55 - 15:00 | Author(s): Hagop Youssoufian
- Abstract
No abstract available for this presentation
-
+
CBL (Sitravatinib) (Slides Available)
15:00 - 15:05 | Author(s): Lyudmila Bazhenova
- Abstract
No abstract available for this presentation
-
+
18 - MET/RET
- Type: General Session
- Track:
- Presentations: 14
- Slides Available
- Moderators:George Blumenschein
- Coordinates: 2/22/2019, 16:40 - 18:00, Starlight Ballroom
-
+
BLU667 (RET) (Slides Available)
15:40 - 15:45 | Author(s): Justin Gainor
- Abstract
No abstract available for this presentation
-
+
RXDX104/015 (RET) (Slides Available)
15:45 - 15:50 | Author(s): Jyoti Patel
- Abstract
No abstract available for this presentation
-
+
Loxo 292 (RET) (Slides Available)
15:50 - 15:55 | Author(s): Alexander Drilon
- Abstract
No abstract available for this presentation
-
+
Multi TKIs (Cabo, Levantinib, Alectinib, Ponatinib) (RET) (Slides Available)
15:55 - 16:00 | Author(s): Adrian Sacher
- Abstract
No abstract available for this presentation
-
+
Crizotinib (MET) (Slides Available)
16:00 - 16:05 | Author(s): Mark Kris
- Abstract
No abstract available for this presentation
-
+
Capmatinib (MET) (Slides Available)
16:05 - 16:10 | Author(s): Rebecca Heist
- Abstract
No abstract available for this presentation
-
+
Tepotinib (MET) (Slides Available)
16:10 - 16:15 | Author(s): Xiuning Le
- Abstract
No abstract available for this presentation
-
+
Cabozantinib (MET) (Slides Available)
16:15 - 16:20 | Author(s): Joel Neal
- Abstract
No abstract available for this presentation
-
+
Savolitinib (MET) (Slides Available)
16:20 - 16:25 | Author(s): Mark Awad
- Abstract
No abstract available for this presentation
-
+
Emibetuzumab (MET) (Slides Available)
16:25 - 16:30 | Author(s): Ron Natale
- Abstract
No abstract available for this presentation
-
+
Sym015 (MET) (Slides Available)
16:30 - 16:35 | Author(s): Ross Camidge
- Abstract
No abstract available for this presentation
-
+
TPX0022 (MET) (Slides Available)
16:35 - 16:40 | Author(s): Joel Neal
- Abstract
No abstract available for this presentation
-
+
Merestinib (AXL) (Slides Available)
16:40 - 16:45 | Author(s): Mark Awad
- Abstract
No abstract available for this presentation
-
+
Science (Slides Available)
16:45 - 16:55 | Author(s): Trever Bivona
- Abstract
No abstract available for this presentation
-
+
19 - Debate #3 Optimal Therapy After Progression on Osimertinib with No New Driver is Chemotherapy Alone
- Type: General Session
- Track:
- Presentations: 2
- Slides Available
- Moderators:Ravi Salgia
- Coordinates: 2/22/2019, 18:05 - 18:20, Starlight Ballroom
-
+
No - Chemo + IO + Bev
17:05 - 17:20 | Author(s): Karen Kelly
- Abstract
No abstract available for this presentation
-
+
Yes - Chemo Alone (Slides Available)
17:05 - 17:20 | Author(s): Frances Shepherd
- Abstract
No abstract available for this presentation
-
+
20 - Mesothelioma
- Type: General Session
- Track:
- Presentations: 7
- Slides Available
- Moderators:Eva Szabo
- Coordinates: 2/22/2019, 18:20 - 19:10, Starlight Ballroom
-
+
Immunotherapy Combos (Slides Available)
17:20 - 17:25 | Author(s): Anne Tsao
- Abstract
No abstract available for this presentation
-
+
Immunotherapy + Chemo (Slides Available)
17:25 - 17:30 | Author(s): Patrick Forde
- Abstract
No abstract available for this presentation
-
+
Brentuximab (Slides Available)
17:30 - 17:35 | Author(s): Anne Tsao
- Abstract
No abstract available for this presentation
-
+
Pembrolizumab + Anetumab Ravtansine (Slides Available)
17:35 - 17:40 | Author(s): Aaron Mansfield
- Abstract
No abstract available for this presentation
-
+
WT1 Peptide Vaccine and CAR (Slides Available)
17:40 - 17:45 | Author(s): Matthew Gubens
- Abstract
No abstract available for this presentation
-
+
CRS207 + Pembro (Slides Available)
17:45 - 17:50 | Author(s): Jonathan Goldman
- Abstract
No abstract available for this presentation
-
+
Science (Slides Available)
17:50 - 18:00 | Author(s): Harvey Pass
- Abstract
No abstract available for this presentation
first
prev
